Century Therapeutics, Inc. IPSC 深 沪
等待开盘 03-26 09:30:00 美东时间
2.195
-0.045
-2.01%
华盛通- 最 高2.32
- 今 开2.28
- 成交量 54.87万股
- 最 低 2.18
- 昨 收 2.24
- 总市值 3.95亿
- 52周最高 3.04
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 0.3418
- 委 比 -40.07%
- 总股本 1.80亿
- 历史最高 32.899
- 量 比 0.26
- 振 幅 6.25%
- 历史最低 0.3418
- 每 手 1
- 风险率 0.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多iSpecimen Collects 500 Influenza Samples, Showcases Rapid Research Support
iSpecimen Inc. (NASDAQ:ISPC) (the "Company"), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the responsiveness and capabilities of its site
03-16 19:50
Century Therapeutics Q4 EPS $(0.25) Beats $(0.27) Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 8.42 percent. This is a 41.86 percent increase over losses of $(0.43) per share
03-12 20:21
美股牛股 | 获FDA支持加速药物上市！MoonLake大涨27%；Satellogic大涨21.7%
获FDA支持加速药物上市！MoonLake大涨27%；宣布获七位数地球观测合同，Satellogic涨超21%>>
01-09 16:01
Century Therapeutics Launches $135M Private Placement Offering Of ~117M common Shares, Warrants At $1.15/Share
Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced it has entered into
01-08 21:08
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
2025-11-18 15:28
Leerink Partners Downgrades Century Therapeutics to Market Perform, Lowers Price Target to $2
Leerink Partners analyst Daina Graybosch downgrades Century Therapeutics (NASDAQ:IPSC) from Outperform to Market Perform and lowers the price target from $7 to $2.
2025-11-17 20:29
Century Therapeutics Q3 EPS $(0.40) Misses $(0.34) Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.34) by 18.34 percent. This is a 8.11 percent decrease over losses of $(0.37) per share
2025-11-13 20:34
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Century Therapeutics announced that its Chief Scientific Officer, Chad Cowan, Ph.D., will present at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025, in New York. The presentation will be live-streamed on Century’s website and available for replay for 30 days. Century Therapeutics is a biotech company developing iPSC-derived cell therapies for autoimmune diseases and cancer using its Allo-Evasion™ technology. For more inform...
2025-10-14 20:01
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics' CEO Brent Pfeiffenberger will present at the H.C. Wainwright Global Investment Conference on September 9-10, 2025, in New York. An on-demand webcast of the presentation will be available on September 5, 2025, on the company’s website. Century Therapeutics is a biotech company developing iPSC-derived cell therapies for autoimmune diseases and cancers, focusing on off-the-shelf therapies to expand patient access.
2025-08-22 12:00
Century Therapeutics Announces Major Workforce Reduction
An announcement from Century Therapeutics ( ($IPSC) ) is now available. On July...
2025-07-08 04:29
